XIRP2 and hepatocellular carcinoma: These findings suggest that the presence of the XIRP2 mutation may confer the heightened resistance of HCC cells to fludarabine and oxaliplatin while simultaneously enhancing their sensitivity to WEHI-539 and LCL 161.